Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
EORTC (European Organization for Research and Treatment of Cancer)
FDG (fluorodeoxyglucose)
ICI (immune checkpoint inhibitor)
Malignant melanoma
PERCIST (Positron Emission Tomography Response Criteria in Solid Tumors)
PET/CT (positron emission tomography/computed tomography)
Journal
Japanese journal of radiology
ISSN: 1867-108X
Titre abrégé: Jpn J Radiol
Pays: Japan
ID NLM: 101490689
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
24
06
2021
accepted:
12
07
2021
pubmed:
22
7
2021
medline:
8
1
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen's κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939-0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.
Identifiants
pubmed: 34287739
doi: 10.1007/s11604-021-01174-w
pii: 10.1007/s11604-021-01174-w
pmc: PMC8732811
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-85Subventions
Organisme : working group grant of japanese society of nuclear medicine, japan
ID : 2019-1
Informations de copyright
© 2021. The Author(s).
Références
J Nucl Med. 2015 Jun;56(6):955-61
pubmed: 25883122
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
EJNMMI Res. 2019 Jan 29;9(1):8
pubmed: 30694399
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
Sci Rep. 2021 Apr 19;11(1):8517
pubmed: 33875730
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
Radiology. 2003 Aug;228(2):303-8
pubmed: 12819342
J Nucl Med. 2019 Mar;60(3):335-341
pubmed: 30413661
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):17-31
pubmed: 28623376
EJNMMI Res. 2018 Aug 20;8(1):83
pubmed: 30128776